-The Indian Express West Bengal is not new to chit fund scams. What is unique to the Saradha Group scandal is how it targeted the poorest and the most marginalised, leaving them on the verge of devastation. From 17-year-old agents who raised money from depositors to 50-year-old widows who invested money, the Saradha Group didn't discriminate in roping them in. Since the house of cards started collapsing, two agents and two...
More »SEARCH RESULT
Total Matching Records found : 751
The fall of Saradha group revives old ghosts of ponzi schemes going bust -Atmadip Ray
-The Economic Times For many, it is a sense of deja vu. Fifteen years ago, the government and India's financial regulators came under fire after hundreds of crores were cleaned up by a few individuals and entities from gullible investors, who were promised fabulous returns from plantation schemes. In the uproar that followed, the government and the regulators sought to palm off the responsibility of regulation of such schemes on each...
More »Supreme Court and the aam aadmi -G Mohan Gopal
-Frontline It is the goal of social revolution that connects the aam aadmi to the judiciary and to its highest institution, the Supreme Court of India. By Prof. G. MOHAN GOPAL WHAT should be the appropriate mea-sure of the relationship between the apex court of a country and its common people? Should an apex court be evaluated by who invokes its jurisdiction, from which area and for what purpose? Is an apex...
More »Has India lost the 21st century?-Avalok Langer
-Tehelka With 65 percent of the population below the age of 35, India boasts of an unparalleled generational dividend, but are we turning this potential into a disaster? Avalok Langer spots a ticking time bomb Nutrition & Health* 40% of children in India are malnourished 43% of children in the age group of 12-23 months receive full immunisation 48%+ of children are underweight 50%+ of all deaths under age 5 are related to malnutrition 45% of children...
More »Supreme Court rules for cheap cancer drug -Subodh Varma
-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...
More »
